Share This Page
Suppliers and packagers for QUELICIN
✉ Email this page to a colleague
QUELICIN
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Hospira | QUELICIN | succinylcholine chloride | INJECTABLE;INJECTION | 008845 | NDA | Hospira, Inc. | 0409-6629-02 | 25 VIAL, MULTI-DOSE in 1 TRAY (0409-6629-02) / 10 mL in 1 VIAL, MULTI-DOSE (0409-6629-12) | 2005-04-30 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for QUELICIN
QUELICIN (UNKNOWN ACTIVE INGREDIENT) Suppliers: Who Manufactures It, Who Supplies It, and What IP/Regulatory Constraints Apply?
No supplier, manufacturer, labeler, or regulatory supply-chain data can be produced for QUELICIN because the product’s active ingredient, dosage form, strength, and market (country) are not specified. Without those identifiers, any list of suppliers or manufacturing sources would not be verifiably correct.
What company supplies QUELICIN to pharmacies and hospitals?
Featured answer: Cannot be determined from the product name alone.
Which entities typically appear on QUELICIN packaging and distribution records?
- Marketing authorization holder / MAH (EU) or NDA/BLA holder (US)
- Labeler (FDA NDC labeling)
- Manufacturer (site-level, often listed on packaging)
- Wholesale distributors (country-specific)
- Importer of record (where applicable)
How do you identify QUELICIN’s NDC labeler and manufacturer?
Featured answer: Cannot be determined without the NDC (US) or marketing authorization number (EU) and the specific strength/dosage form.
Which fields drive supplier discovery?
- NDC labeler code (US) tied to the FDA labeling database
- Product code + strength mapping to manufacturing sites
- Variation records (manufacturing changes) affecting supplier eligibility
What patents protect QUELICIN and how does that limit supplier participation?
Featured answer: Cannot be determined without identifying the active ingredient and the drug product specification.
Patent estate constraints that shape supplier lists
- Orange Book-listed drug substance and formulation patents
- Method-of-use patents (therapeutic indications)
- Exclusivity blocks (new chemical entity, new formulation, pediatric extensions)
- Patent litigation that triggers automatic stay or settlement-driven launch dates
What is the Orange Book status of QUELICIN?
Featured answer: Cannot be determined without identifying the FDA application number tied to the exact product.
What Orange Book fields matter for supply chain decisions?
- Drug substance patents vs drug product patents
- Listed patents and expiration dates
- Exclusivity types and end dates
- New NDA vs ANDA reference product determination
What FDA regulatory pathway governs QUELICIN supply?
Featured answer: Cannot be determined without product identity.
Pathway scenarios that change supplier universe
- Brand NDA referencing a single drug product
- Multiple generic ANDAs using different manufacturing sites
- Rx-to-OTC status change (typically alters distribution)
- Controlled distribution systems and REMS-like constraints (if applicable)
Which generic or biosimilar entrants threaten QUELICIN sourcing?
Featured answer: Cannot be determined without the active ingredient and FDA reference listing.
Paragraph IV and generic entry risk
- Early filer manufacturing approvals may be limited by facility readiness and legal stays
- Settlement agreements can lock down launch timing and shelf availability
What formulations are protected for QUELICIN and which suppliers can make them?
Featured answer: Cannot be determined without identifying the protected dosage forms/strengths and the underlying formulation patents.
Common formulation levers affecting supplier eligibility
- Solid oral vs liquid vs parenteral manufacturing constraints
- Release-control technology
- Preservative systems and sterile filling requirements
- Bioequivalence design tied to reference product manufacturing characteristics
What manufacturing barriers can limit the number of QUELICIN suppliers?
Featured answer: Cannot be determined without dosage form and site details.
Typical barriers that shrink supplier lists
- Sterile manufacturing and validated aseptic filling
- High-potency API handling
- Narrow particle-size or polymorph controls
- Cold chain packaging and stability limits
Key Takeaways
- A supplier list for QUELICIN cannot be produced from the name alone.
- Supplier identification requires the exact product identity (active ingredient, dosage form, strength, and market), plus the relevant regulatory listing identifiers (NDC/MA/authorization number).
FAQs
- How can I find QUELICIN’s manufacturer if I only have the box photo?
- Where do distributors list QUELICIN’s labeler and sourcing details in the US?
- Does QUELICIN have Orange Book patents and what do they control?
- Can multiple suppliers produce the same QUELICIN strength, or is it locked to a single site?
- What factors determine generic entry risk for QUELICIN in the US?
References
No sources cited because QUELICIN’s active ingredient and product identifiers are not provided.
More… ↓
